摘要
滤泡淋巴瘤(FL)是最常见的惰性B细胞淋巴瘤。2023年美国血液学会(ASH)年会公布多项关于初诊及难治复发FL的最新研究进展,包括靶向治疗、双特异性抗体、嵌合抗原受体T细胞(CAR-T)治疗等。文章结合会议报道将对这些进展进行综述。
Follicular lymphoma(FL)is the most common indolent B-cell lymphoma.The 2023 American Society of Hematology(ASH)annual meeting announced the latest updates on newly diagnosed and relapsed/refractory FL,including the targeted therapy,bio-specific antibodies and chimeric antigen receptor T-cell(CAR-T)therapy.This review provides an overview of these updates.
作者
林志娟
徐兵
Lin Zhijuan;Xu Bing(Department of Hematology,the First Affiliated Hospital of Xiamen University,Hematology Branch,Xiamen University,Quality Controlling Center of Hematology in Xiamen,Key Laboratory of Accurate Diagnosis and Treatment of Blood in Xiamen,Xiamen 361003,China)
出处
《白血病．淋巴瘤》
CAS
2024年第3期138-141,共4页
Journal of Leukemia & Lymphoma
基金
国家自然科学基金(U22A20290、82170180)。
关键词
淋巴瘤
滤泡性
复发
难治
美国血液学会
治疗结果
Lymphoma,follicular
Recurrence
Refractory
American Society of Hematology
Treatment outcome
